ESTRO 2025 - Abstract Book

S1400

Clinical - Lung

ESTRO 2025

analysis, no statistically significant differences were identified between the SBRT and the surgery arm, except for the ECOG score, the Charlson Comorbidity Index and PCR values.

Conclusion: Differences in performance status and comorbidity rates were expected based on clinical experience, but overall the analysis of the first 100 patients of the MONDRIAN study suggest that no selection bias has been introduced so far. The involvement of a second institution is planned to correct the current unbalance between the SBRT and the surgical cohort. While the enrollment continues, translational analyses are underway, and preliminary results will soon be available exploring the association with clinical parameters.

Keywords: early-stage NSCLC, SBRT, multi-omics

3562

Digital Poster Chemo-radiation involving Oral Vinorelbine in Lung Cancer: An Alternative Schedule for Elderly Patients José J Cantillana, Marta M López, Arancha A Gallego, Susana S Sánchez, Sara S Pérez, Carlota C Cascajares, María Ángeles M.A Ruiz, María Isabel M.I. García Radiation Oncology, Hospital Universitario Puerta de Hierro, Madrid, Spain Purpose/Objective: This study aims to evaluate the response and toxicity rates in elderly patients with comorbidities treated with concomitant chemoradiotherapy based on oral vinorelbine for local or locally advanced lung cancer. Material/Methods: From 2016 to 2024, 31 lung cancer patients (Squamous-cell, Adenocarcinoma, Pleomorphic, Neuroendocrine) were treated with concomitant chemoradiotherapy involving oral vinorelbine. Mean age: 75.45y (54-90). Comorbidities were assessed using the G8 frailty scale (³7.5 in 100%), COPD diagnosis and severity (94% ³G1), heart disease (44%), and Charlson Comorbidity Index (³8 in 93.6%). Radiotherapy (55, 60, or 66Gy) was administered with 1-7 cycles of oral vinorelbine. Treatment tolerance was evaluated by pneumonitis, esophagitis, diarrhea, anemia, and neutropenia incidence and severity. Local and distant disease-free survival within two years were analyzed.

The impact of clinical features, loco-regional relapse (LRR), metastases, and overall-survival were investigated. Statistical analysis included Kaplan-Meier method, log-rank test, and Chi-square test.

Results: Patients (71% squamous, 29% non-squamous) had a median follow-up of 26 months. One-year and two-year thoracic relapse-free survival (TRFS) were 80% and 47%, respectively. One-year and two-year distant relapse-free survival (DRFS) were 77% and 52%, respectively. Most of the diagnoses were locally advanced (Stage III, 77.5%).

Patients well-tolerated the treatment: 61% had esophagitis (G1: 29%, G2: 32%), only 3.3% had G1 pneumonitis, 6.4% had diarrhea (G1:3.2%, G2:3.2%), 16.1% had G1 anemia, and 16.1% had neutropenia (G1: 12.9%, G2: 3.2%).

Conclusion: Concomitant chemoradiotherapy founded on oral vinorelbine is shown as a via alternative for elderly patients with comorbidities, providing good control rates and excellent tolerance.